{"gene":"FLCN","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":2006,"finding":"FLCN (folliculin) interacts directly with FNIP1 (folliculin-interacting protein 1), which in turn interacts with AMPK. FNIP1 is phosphorylated by AMPK, and FLCN phosphorylation is regulated by both mTOR (reduced by rapamycin and amino acid starvation) and AMPK signaling, placing FLCN in the AMPK-mTOR nutrient-sensing pathway.","method":"Co-immunoprecipitation, mass spectrometry identification of FNIP1, in vitro phosphorylation assays, AMPK inhibitor/rapamycin treatment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, MS interactome, biochemical phosphorylation assays; foundational paper replicated widely","pmids":["17028174"],"is_preprint":false},{"year":2009,"finding":"Homozygous loss of BHD/FLCN causes embryonic lethality at E5.5-E6.5 in mice. Kidney tumors from BHD heterozygous knockout mice and human BHD patients show activation of both mTORC1 and mTORC2, and elevated total AKT protein (without increased mRNA), suggesting FLCN regulates AKT post-translationally or post-transcriptionally.","method":"Mouse knockout model (homozygous and heterozygous), immunoblotting for mTORC1/mTORC2 substrates, qRT-PCR, LOH analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular/developmental phenotype plus molecular pathway analysis; replicated in multiple tumor types","pmids":["19850877"],"is_preprint":false},{"year":2008,"finding":"Kidney-specific deletion of BHD/FLCN in mice activates the mTOR pathway, and rapamycin treatment suppresses cystogenesis and extends survival, establishing FLCN as a functional upstream negative regulator of mTOR in renal cells.","method":"Conditional kidney-specific knockout (Ksp-Cre), rapamycin treatment rescue experiment, histological and biochemical analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with defined phenotypic rescue by mTOR inhibitor; strong causal pathway evidence","pmids":["18974783"],"is_preprint":false},{"year":2010,"finding":"FLCN inactivation causes increased nuclear localization of TFE3 (accompanied by decreased TFE3 phosphorylation), leading to elevated TFE3 transcriptional activity and upregulation of GPNMB expression. This establishes TFE3 nuclear translocation as a downstream consequence of FLCN loss.","method":"FLCN knockdown/restoration in renal cancer cells, TFE3 knockdown, immunostaining of TFE3 in cells/mouse kidneys/human tumors, mRNA/protein expression analysis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (KD, reconstitution, immunostaining in multiple model systems); replicated in subsequent studies","pmids":["21209915"],"is_preprint":false},{"year":2019,"finding":"FLCN-FNIP2 functions as a GTPase-activating protein (GAP) for RagC/D GTPases. Cryo-EM structure of the FLCN-FNIP2-Rag-Ragulator complex reveals that FLCN and FNIP2 adopt an extended conformation with Longin domains heterodimerizing and contacting Rag nucleotide-binding domains, while DENN domains interact distally. A conserved arginine on FLCN acts as the catalytic arginine finger for RagC/D GAP activity.","method":"Cryo-EM structure determination, biochemical GAP activity assays, mutagenesis of catalytic arginine","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structure with biochemical validation and mutagenesis in a single rigorous study","pmids":["31704029"],"is_preprint":false},{"year":2022,"finding":"Cryo-EM structure of the active FLCN complex (AFC) containing FLCN, FNIP2, SLC38A9 N-terminal tail, RagA(GDP):RagC(GDP·BeFx), and Ragulator reveals that during GAP activation FLCN reorients ~90° relative to the inactive lysosomal complex, breaks contact with RagA, and makes new contacts with RagC that position Arg164 for catalysis. Disruption of AFC-specific FLCN-RagC interfaces eliminates GAP activity and causes nuclear retention of TFE3 without affecting S6K or 4E-BP1 phosphorylation, demonstrating substrate-selective mTORC1 regulation.","method":"Cryo-EM structure determination, mutagenesis of interface residues, GAP activity assays, TFE3 localization assays","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structure plus mutagenesis and functional validation; demonstrates mechanistic basis for substrate selectivity","pmids":["36103527"],"is_preprint":false},{"year":2018,"finding":"FLCN-FNIP complex is recruited to lysosomes during amino acid starvation in a manner dependent on GATOR1 GAP activity toward RagA/B (which converts RagA/B to GDP-bound state). By binding RagA/B(GDP) and acting as a GAP on RagC/D, the FLCN-FNIP complex coordinates nucleotide status between Rag heterodimer subunits in response to amino acid availability.","method":"Lysosomal fractionation, RagA/B nucleotide-loading mutants, GATOR1 knockdown, co-immunoprecipitation","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods defining FLCN lysosomal recruitment mechanism and epistatic relationship with GATOR1","pmids":["29848618"],"is_preprint":false},{"year":2016,"finding":"Adipose-specific deletion of FLCN relieves mTOR-dependent cytoplasmic retention of TFE3, leading to nuclear TFE3 and direct induction of PGC-1α/PGC-1β, driving mitochondrial biogenesis and adipose browning. This FLCN-mTOR-TFE3-PGC-1β pathway is separable from canonical TSC-mTOR-S6K signaling and is driven by RagC/D.","method":"Adipose-specific conditional KO, TFE3 and PGC-1β co-deletion rescue, inducible PGC-1β expression, amino acid sensitivity assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis via multiple conditional KO combinations with defined molecular and physiological readouts","pmids":["27913603"],"is_preprint":false},{"year":2016,"finding":"Adipose-specific loss of FLCN causes chronic hyperactivation of AMPK, which in turn induces and activates PGC-1α and ERRα, driving mitochondrial biogenesis and browning of white adipose tissue through the AMPK/PGC-1α/ERRα axis.","method":"Adipose-specific FLCN knockout mouse, AMPK activity assays, gene expression analysis, metabolic phenotyping","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with defined molecular pathway; complementary to other adipose FLCN study from same year","pmids":["27151976"],"is_preprint":false},{"year":2012,"finding":"Muscle-targeted FLCN knockout leads to increased mitochondrial biogenesis and oxidative phosphorylation in a PGC-1α (PPARGC1A)-dependent manner. Reconstitution of FLCN-null kidney cancer cells with wild-type FLCN suppresses mitochondrial metabolism and PGC-1α expression, establishing FLCN as a negative regulator of PGC-1α-driven mitochondrial oxidative metabolism.","method":"Conditional muscle/kidney KO mice, PPARGC1A double KO rescue, electron microscopy, oxygen consumption measurement, FLCN reconstitution in null cells","journal":"Journal of the National Cancer Institute","confidence":"High","confidence_rationale":"Tier 2 — multiple conditional KO systems with genetic rescue and in vitro reconstitution","pmids":["23150719"],"is_preprint":false},{"year":2021,"finding":"GABARAP (but not LC3) directly binds to a previously unidentified LIR motif in the FLCN/FNIP complex, sequestering it to GABARAP-conjugated membrane compartments during autophagy (CASM, mitophagy, xenophagy). This disrupts FLCN/FNIP GAP function toward RagC/D, resulting in impaired mTOR-dependent phosphorylation of TFEB, thereby activating TFEB/TFE3 to control lysosomal capacity.","method":"Co-IP identifying GABARAP-FLCN interaction, LIR motif identification/mutagenesis, GABARAP-specific vs. LC3-specific depletion, TFEB phosphorylation assays","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 — direct binding identification with LIR motif mutagenesis plus functional GAP activity and phosphorylation readouts","pmids":["34597140"],"is_preprint":false},{"year":2014,"finding":"FLCN interacts with GABARAP (autophagy protein), and this interaction is modulated by FNIP1 or FNIP2. ULK1 phosphorylates FLCN at Ser406, Ser537, and Ser542. Loss of FLCN impairs basal autophagic flux; re-expression of FLCN rescues autophagy.","method":"Co-IP (FLCN-GABARAP), in vitro ULK1 phosphorylation assay with site identification by mass spectrometry, autophagic flux assays with LC3/SQSTM1","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro phosphorylation with site mapping, reciprocal Co-IP, functional autophagy readouts","pmids":["25126726"],"is_preprint":false},{"year":2009,"finding":"FLCN phosphorylation is regulated downstream of the TSC2-mTORC1 axis: downregulation of tuberin or Rheb expression induces multiple FLCN phosphorylation events. Phosphorylation at Ser62 and Ser302 are differentially regulated by mTORC1-dependent pathways, and FLCN phosphorylation state modulates its complex formation with AMPK.","method":"Tuberin/Rheb overexpression/knockdown with immunoblotting for FLCN phospho-sites, co-immunoprecipitation of FLCN-AMPK complex","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — direct phospho-site analysis with multiple genetic perturbations; single lab, limited orthogonal validation","pmids":["19695222"],"is_preprint":false},{"year":2019,"finding":"FLCN and AMPK act upstream of TFEB/TFE3 in the innate immune response independently of mTORC1. Loss of FLCN or pharmacological AMPK activation induces TFEB/TFE3-dependent pro-inflammatory cytokine expression in mammalian macrophages; LPS treatment causes acute AMPK activation accompanied by TFEB nuclear localization.","method":"C. elegans FLCN ortholog loss-of-function, mammalian FLCN KO cells, AMPK pharmacological activation, TFEB/TFE3 knockdown, cytokine/reporter assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis across two model organisms plus mammalian cells with multiple orthogonal readouts","pmids":["30917316"],"is_preprint":false},{"year":2015,"finding":"In C. elegans, loss of FLCN-1 (FLCN ortholog) increases resistance to hyperosmotic stress via constitutive AMPK-dependent accumulation of glycogen; upon stress, glycogen is degraded to glycerol. This pathway requires glycogen synthase, glycogen phosphorylase, and GPDH enzymes. Glycogen accumulates in kidneys from FLCN-knockout mice and BHD patient renal tumors.","method":"C. elegans FLCN-1 loss-of-function, double mutants with AMPK/glycogen metabolism genes (epistasis), mouse kidney fractionation, BHD patient tumor analysis","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in C. elegans with multiple double-mutant rescue experiments; validated in mammalian tissue","pmids":["26439621"],"is_preprint":false},{"year":2006,"finding":"The Drosophila BHD homolog (DBHD) is required for male germline stem cell (GSC) maintenance. RNAi-mediated reduction of DBHD suppresses GSC overproliferation caused by overexpression of JAK-STAT ligand (upd) or BMP ligand (dpp), placing DBHD downstream or in parallel of JAK/STAT and Dpp signaling pathways.","method":"RNAi knockdown in Drosophila testis, genetic interaction assays with upd/dpp overexpression (epistasis), GSC counting","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis in Drosophila ortholog; single organism, defined pathway placement","pmids":["16636660"],"is_preprint":false},{"year":2014,"finding":"Cardiac-specific loss of FLCN causes severe cardiac hypertrophy with mTORC1 upregulation; rapamycin treatment reduces heart mass. FLCN deficiency reduces phospho-AMPK (T172) and elevates PGC-1α (PPARGC1A), increasing mitochondrial metabolism. Inactivation of PPARGC1A in FLCN-deficient hearts restores phospho-AMPK levels and suppresses mTORC1, establishing a FLCN-PPARGC1A-AMPK-mTORC1 axis in cardiac hypertrophy.","method":"Cardiac-specific conditional KO, PPARGC1A double KO rescue, rapamycin treatment, AMPK activity assays, ATP level measurement","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — multiple conditional KO and rescue experiments establishing epistasis, with pharmacological validation","pmids":["24908670"],"is_preprint":false},{"year":2010,"finding":"FLCN reconstitution in FLCN-null renal cells suppresses tumor formation in nude mice and upregulates TGF-β signaling components (TGFB2, INHBA/activin A, THBS1, SMAD3). Activin A (INHBA homodimer) completely suppresses anchorage-independent growth of FLCN-null cells, identifying TGF-β/activin signaling as a downstream effector of FLCN tumor suppression.","method":"Stable FLCN re-expression in null cell line, nude mouse xenograft, gene expression profiling, anchorage-independent growth assay","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 — reconstitution plus functional assay; single lab, pathway placement via differential expression and functional rescue","pmids":["20573232"],"is_preprint":false},{"year":2011,"finding":"FLCN directly interacts with TDP-43 via FLCN amino acids 202-299 binding to the RRM domains of TDP-43. Both exogenous and endogenous FLCN promote TDP-43 cytoplasmic translocation, protein aggregation, and stress granule formation.","method":"Co-immunoprecipitation, domain mapping by deletion constructs, FLCN knockdown and overexpression with TDP-43 localization assays, stress granule imaging","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 3 — direct binding with domain mapping and functional localization assay; single lab","pmids":["26516189"],"is_preprint":false},{"year":2011,"finding":"FLCN, MAPO1 (FNIP2), and AMPK form a complex required for apoptosis induced by O6-methylguanine alkylation. After MNU treatment, AMPKα phosphorylation occurs in an MLH1-dependent manner and requires both MAPO1 and FLCN expression; AICAR-induced AMPK activation is also MAPO1- and FLCN-dependent.","method":"siRNA knockdown of FLCN/MAPO1/AMPK, sub-G1 DNA content assay, AICAR/MNU treatment, mitochondrial membrane potential assay","journal":"DNA repair","confidence":"Medium","confidence_rationale":"Tier 2 — genetic loss-of-function plus pharmacological activation with defined molecular readouts; single lab","pmids":["22209521"],"is_preprint":false},{"year":2017,"finding":"FNIP2 protein is degraded via β-TRCP/CK1-directed ubiquitination in a nutrition-dependent manner. FNIP2 degradation leads to lysosomal dissociation of FLCN and subsequent lysosomal association of mTOR, promoting renal cancer cell proliferation.","method":"Ubiquitination assays, β-TRCP co-IP, lysosomal fractionation, CK1 inhibition","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical ubiquitination assay with fractionation showing functional consequence; single lab","pmids":["28039480"],"is_preprint":false},{"year":2018,"finding":"FLCN binds to Rab11A through its C-terminal DENN-like domain and promotes loading of the amino acid transporter PAT1 onto Rab11A-positive recycling vesicles, maintaining PAT1 on the plasma membrane rather than at lysosomes, thereby sustaining lysosomal amino acid signaling and mTORC1 activity.","method":"Co-IP of FLCN-Rab11A, domain mapping, in vitro GEF assay (negative result), PAT1 localization by imaging, mTORC1 activity assays","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding with domain mapping, in vitro assay, and functional localization consequence; single lab","pmids":["30446510"],"is_preprint":false},{"year":2021,"finding":"FLCN promotes Rab11A binding to transferrin receptor 1 (TfR1) to facilitate TfR1 recycling transport. Loss of FLCN attenuates Rab11A-TfR1 interaction, delays TfR1 recycling, causes iron deficiency, and induces HIF activity. Iron supplementation reverses HIF activation in FLCN-deficient cells; dietary iron rescues BHD phenotype in Drosophila.","method":"Co-IP (FLCN-Rab11A-TfR1), FLCN KO cells, TfR1 recycling assay, HIF reporter, Drosophila dietary rescue","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal Co-IP, functional recycling assay, in vivo Drosophila rescue; single lab","pmids":["33609526"],"is_preprint":false},{"year":2016,"finding":"FLCN maintains the leucine level within lysosomes by inhibiting accumulation of the amino acid transporter PAT1 on the lysosome surface, thereby sustaining lysosomal leucine as a signal to activate mTORC1. Supplementation with high leucine (but not other amino acids) rescues mTORC1 activity lost upon FLCN suppression.","method":"FLCN knockdown/overexpression in HEK293, lysosomal leucine measurement, PAT1 localization assays, amino acid rescue experiments","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — amino acid-specific rescue plus transporter localization analysis; single lab","pmids":["27280402"],"is_preprint":false},{"year":2019,"finding":"AMPK promotes expression of FLCN through activation of TFEB (independently of mTOR), identifying a novel AMPK-TFEB-FLCN axis. AMPK-induced FLCN expression is abolished in MEFs lacking TFEB/TFE3, and mutation of the putative TFEB-binding site in the FLCN promoter reduces promoter activity. This axis is conserved in zebrafish.","method":"Whole-genome transcriptome profiling, TFEB/TFE3 double KO MEFs, promoter-luciferase reporter assay with TFEB site mutation, zebrafish AMPK KO model","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — transcriptomics plus promoter mutagenesis and genetic KO validation; single lab","pmids":["31404503"],"is_preprint":false},{"year":2020,"finding":"FLCN loss in hematopoietic cells activates TFE3, which stimulates glycogenesis by transcriptionally upregulating glycogenesis genes (Gys1, Gyg). TFE3 also transcriptionally activates FLCN expression (feedback loop). Tfe3 deletion in FLCN-KO mice reduces phagocyte expansion and LSD-like phenotypes, establishing a FLCN-TFE3 rheostat controlling lysosome activity and glycogenesis.","method":"Hematopoietic-lineage conditional Flcn KO, Tfe3/Flcn double KO rescue, ChIP/transcriptional target analysis, metabolite analysis","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — genetic double-KO epistasis with defined molecular (transcriptional targets) and cellular phenotypes","pmids":["32049013"],"is_preprint":false},{"year":2020,"finding":"Genetic deficiency of FLCN in mice leads to nuclear translocation of TFE3 in venous endothelial cells, which drives ectopic expression of Prox1 (master transcription factor for lymphatic specification) by binding a regulatory element in the Prox1 gene, causing misconnection of blood and lymphatic vessels.","method":"Endothelial-specific Flcn KO mouse, TFE3 ChIP on Prox1 regulatory element, Prox1 expression analysis, vascular phenotype characterization","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with ChIP demonstrating direct TFE3 binding to Prox1 regulatory element; defined vascular phenotype","pmids":["33298956"],"is_preprint":false},{"year":2019,"finding":"Loss of FLCN in human renal tubular epithelial cells activates TFE3 (upregulating RRAGD and GPNMB) without modifying bulk mTORC1 activity, and independently induces STAT1/STAT2-dependent interferon response genes via increased STAT2 chromatin recruitment, slowing cellular proliferation.","method":"CRISPR KO of FLCN/FNIP1/FNIP2 in RPTEC/TERT1 cells, RNA-seq, ChIP-seq (STAT2), TFE3 nuclear localization, proliferation assays","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — CRISPR KO with ChIP-seq demonstrating direct STAT2 chromatin recruitment; multiple orthogonal methods","pmids":["33459596"],"is_preprint":false},{"year":2019,"finding":"Loss of FLCN in mouse embryonic fibroblasts and lung fibroblasts inhibits canonical WNT signaling via TFE3: FLCN deficiency decreases Wnt2/Wnt7b expression and TCF/LEF activity; silencing TFE3 completely reverses this phenotype whereas constitutively active β-catenin only partially rescues it.","method":"Flcn KO in MEFs and MRC-5 cells, RNA-seq, TCF/LEF reporter assay, TFE3 siRNA rescue, active β-catenin rescue","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with TFE3 rescue epistasis establishing pathway; single lab","pmids":["31272105"],"is_preprint":false},{"year":2017,"finding":"FLCN H255Y missense mutation fails to rescue multi-cystic kidney phenotype in Flcn-KO mice, demonstrating loss of tumor suppressor function. The FLCN K508R missense mutation partially rescues but can also cause cystic kidneys and cardiac hypertrophy in heterozygous KO mice, suggesting a dominant negative effect on wild-type FLCN function.","method":"BAC recombineering transgenic rescue in kidney-specific Flcn KO mice, histological phenotype analysis","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo transgenic rescue with defined tissue phenotypes; single lab","pmids":["28007907"],"is_preprint":false},{"year":2011,"finding":"Pathogenic FLCN missense and in-frame deletion mutations significantly disrupt the stability of the FLCN protein product, while missense variants that do not impair protein stability also do not impair tumor suppressor activity or intracellular localization, indicating that protein stability is a key determinant of folliculin tumor suppressor function.","method":"In vitro protein stability assays, growth suppression assay, intracellular localization by fluorescence microscopy, evolutionary conservation analysis","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays correlating stability with tumor suppressor activity; single lab","pmids":["21538689"],"is_preprint":false},{"year":2017,"finding":"A splice-site mutation (c.1177-5_-3delCTC) causes exon 11 skipping in FLCN, producing a truncated protein that is strongly destabilized (reversible by proteasomal and lysosomal degradation inhibitors) and has altered subcellular localization compared to wild-type FLCN.","method":"Minigene splicing assay, TALEN-mediated transgenesis in cultured cells, protein stability assays with inhibitors, subcellular localization by immunofluorescence","journal":"BMC medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 — minigene assay, transgenesis, and biochemical characterization of mutant protein; single lab","pmids":["28499369"],"is_preprint":false},{"year":2023,"finding":"FLCN is phosphorylated at Ser62 by AKT1 (downstream of insulin/mTORC2). RagD-specific recruitment of mTORC2-AKT1 to lysosomes is required for insulin-stimulated FLCN phosphorylation. FLCN Ser62 phosphorylation inhibits RagC GTPase activity and is essential for insulin-induced mTORC1 activation, identifying FLCN as a cross-talk node between amino acid and growth factor (insulin) mTORC1 activation pathways.","method":"Phosphorylation site identification, AKT1 kinase assays, lysosomal fractionation, RagD mutants, mTORC1 activity assays, in vivo tumor growth assays","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical kinase assay with site mapping and genetic validation; single lab","pmids":["37083230"],"is_preprint":false},{"year":2023,"finding":"PRDM10 directly binds a regulatory motif in the FLCN promoter to control FLCN mRNA and protein expression. The pathogenic PRDM10 Cys677Tyr variant loses affinity for this FLCN promoter binding motif, abolishing cellular FLCN expression.","method":"Promoter binding assay, PRDM10 variant functional analysis, FLCN mRNA/protein quantification in cells overexpressing wild-type vs. mutant PRDM10","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — direct promoter binding demonstrated with functional consequence on FLCN expression; single lab","pmids":["36440963"],"is_preprint":false}],"current_model":"FLCN (folliculin) is a tumor suppressor that functions as the catalytic subunit of the FLCN-FNIP1/2 heterodimeric GTPase-activating protein (GAP) complex for RagC/D GTPases; during amino acid sufficiency, FLCN-FNIP is recruited to lysosomes via GATOR1-dependent sensing of RagA/B-GDP, where it activates RagC/D to drive Rag heterodimer-dependent mTORC1 activation specifically toward MiT/TFE substrates (TFEB/TFE3), while loss of FLCN causes nuclear TFE3/TFEB accumulation, upregulation of PGC-1α-driven mitochondrial biogenesis, and AMPK hyperactivation; FLCN is itself phosphorylated by mTOR and AKT1 (at Ser62), regulated by AMPK, subject to ULK1-dependent phosphorylation during autophagy, and sequestered by GABARAP to disrupt its GAP function during autophagic flux, placing FLCN at a critical intersection of amino acid sensing, growth factor signaling, lysosomal homeostasis, and mitochondrial metabolism."},"narrative":{"teleology":[{"year":2006,"claim":"Identification of FNIP1 as a direct FLCN-binding partner that bridges FLCN to AMPK, and demonstration that FLCN phosphorylation is regulated by both mTOR and AMPK, placed FLCN within the nutrient-sensing signaling network for the first time.","evidence":"Co-immunoprecipitation, mass spectrometry identification of FNIP1, phosphorylation assays with rapamycin/AMPK inhibitors in mammalian cells","pmids":["17028174"],"confidence":"High","gaps":["Kinase directly phosphorylating FLCN not yet identified","Functional consequence of FLCN phosphorylation unknown","Whether FLCN-FNIP complex has enzymatic activity unresolved"]},{"year":2008,"claim":"Kidney-specific Flcn knockout demonstrated that FLCN is a bona fide upstream negative regulator of mTOR in vivo, with rapamycin rescuing the cystic phenotype, establishing the first causal tissue-level pathway link.","evidence":"Conditional kidney-specific KO mice (Ksp-Cre) with rapamycin rescue","pmids":["18974783"],"confidence":"High","gaps":["Mechanism of mTOR activation upon FLCN loss unknown","Whether FLCN acts directly on mTOR or through intermediaries unresolved"]},{"year":2009,"claim":"Homozygous FLCN loss causes embryonic lethality, and heterozygous tumors show dual mTORC1/mTORC2 activation with elevated AKT protein, revealing that FLCN loss deregulates both mTOR complexes and may stabilize AKT post-translationally.","evidence":"BHD knockout mice (homozygous and heterozygous), immunoblotting for mTORC1/mTORC2 substrates, qRT-PCR","pmids":["19850877"],"confidence":"High","gaps":["Mechanism of AKT protein stabilization unknown","Whether mTORC2 activation is a direct or indirect consequence of FLCN loss not determined"]},{"year":2010,"claim":"Discovery that FLCN loss causes nuclear TFE3 accumulation and transcriptional activation identified the first specific transcription factor target downstream of FLCN, shifting the field beyond generic mTOR activation toward a substrate-selective model.","evidence":"FLCN knockdown/reconstitution in renal cancer cells, TFE3 localization in cells/mouse kidneys/human tumors","pmids":["21209915"],"confidence":"High","gaps":["Mechanism linking FLCN to TFE3 phosphorylation not known","Whether TFEB is similarly regulated not tested","RagC/D involvement not yet suspected"]},{"year":2012,"claim":"Tissue-specific knockouts established FLCN as a negative regulator of PGC-1α-driven mitochondrial biogenesis, linking FLCN tumor suppression to metabolic reprogramming.","evidence":"Muscle-specific Flcn KO with PGC-1α double-KO rescue, oxygen consumption measurements, FLCN reconstitution in kidney cancer cells","pmids":["23150719"],"confidence":"High","gaps":["Whether PGC-1α induction is a direct transcriptional effect of TFE3 or an indirect consequence not resolved","Relative contribution of AMPK vs. TFE3 to PGC-1α induction unclear"]},{"year":2014,"claim":"Identification of FLCN-GABARAP interaction and ULK1-mediated phosphorylation of FLCN at Ser406/Ser537/Ser542 linked FLCN directly to the autophagy machinery, and loss of FLCN was shown to impair basal autophagic flux.","evidence":"Co-IP of FLCN-GABARAP, in vitro ULK1 kinase assay with mass spectrometry site mapping, autophagic flux assays","pmids":["25126726"],"confidence":"High","gaps":["Functional consequence of individual ULK1 phosphorylation sites not determined","How FLCN promotes autophagic flux mechanistically undefined"]},{"year":2016,"claim":"Two complementary adipose-specific knockout studies resolved parallel downstream pathways: one showing FLCN restrains TFE3-PGC-1β-driven browning via RagC/D (separable from TSC-S6K signaling), the other showing FLCN restrains AMPK-PGC-1α/ERRα-driven mitochondrial biogenesis, together establishing FLCN as a dual-axis metabolic gatekeeper.","evidence":"Adipose-specific Flcn KO with TFE3/PGC-1β double-KO rescue, and separate adipose Flcn KO with AMPK activity assays and metabolic phenotyping","pmids":["27913603","27151976"],"confidence":"High","gaps":["Whether the TFE3/RagC and AMPK axes are independent or converge at a single node is unresolved","Relative in vivo contribution of each axis in kidney tumorigenesis unknown"]},{"year":2018,"claim":"The discovery that FLCN-FNIP is recruited to lysosomes in a GATOR1-dependent manner by sensing RagA/B-GDP established the molecular logic of how amino acid status is read by FLCN to coordinate Rag heterodimer nucleotide states.","evidence":"Lysosomal fractionation, RagA/B nucleotide-loading mutants, GATOR1 knockdown, co-immunoprecipitation","pmids":["29848618"],"confidence":"High","gaps":["Structural basis of FLCN recognition of RagA-GDP not yet determined","Whether other signals besides GATOR1 regulate FLCN lysosomal recruitment unknown"]},{"year":2019,"claim":"Cryo-EM structure of the inactive FLCN-FNIP2-Rag-Ragulator complex revealed the catalytic arginine finger mechanism of FLCN GAP activity toward RagC/D, providing the first atomic-level understanding of FLCN's enzymatic function.","evidence":"Cryo-EM at near-atomic resolution, mutagenesis of catalytic arginine, in vitro GAP assays","pmids":["31704029"],"confidence":"High","gaps":["Complex captured in inactive conformation; the active GAP transition state not yet visualized","Whether FNIP1 and FNIP2 confer different catalytic properties unresolved"]},{"year":2019,"claim":"FLCN-AMPK-TFE3 axis was shown to operate in innate immunity independently of mTORC1, with FLCN loss or AMPK activation inducing TFEB/TFE3-dependent pro-inflammatory cytokine expression in macrophages, broadening FLCN's role beyond metabolic sensing to immune regulation.","evidence":"C. elegans FLCN ortholog mutants, mammalian FLCN KO macrophages, pharmacological AMPK activation, TFEB/TFE3 knockdown, cytokine assays","pmids":["30917316"],"confidence":"High","gaps":["Whether FLCN-dependent immune phenotypes contribute to BHD disease manifestations unknown","Mechanism by which AMPK activates TFEB/TFE3 independently of mTORC1 not defined"]},{"year":2021,"claim":"GABARAP was found to sequester FLCN-FNIP via a LIR motif during autophagy (CASM, mitophagy, xenophagy), explaining how autophagic flux activates TFEB by physically displacing FLCN from its Rag substrates — a key mechanistic link between autophagy and lysosomal biogenesis.","evidence":"GABARAP-FLCN co-IP, LIR motif mutagenesis, GABARAP-specific vs. LC3-specific depletion, TFEB phosphorylation assays","pmids":["34597140"],"confidence":"High","gaps":["Whether GABARAP-FLCN sequestration occurs on specific membrane compartments in vivo not fully mapped","Quantitative contribution relative to other TFEB activation mechanisms unclear"]},{"year":2022,"claim":"Cryo-EM of the active FLCN complex revealed a ~90° reorientation of FLCN that breaks RagA contact and positions Arg164 for RagC catalysis; disruption of active-complex interfaces eliminated GAP activity and caused nuclear TFE3 retention without affecting S6K/4E-BP1, providing the structural basis for substrate-selective mTORC1 regulation.","evidence":"Cryo-EM of FLCN-FNIP2-SLC38A9-Rag-Ragulator active complex, interface mutagenesis, TFE3 localization and mTORC1 substrate phosphorylation assays","pmids":["36103527"],"confidence":"High","gaps":["How SLC38A9 triggers the conformational switch in FLCN mechanistically unclear","Whether additional regulators facilitate the inactive-to-active transition in vivo unknown"]},{"year":2023,"claim":"AKT1 was identified as the kinase phosphorylating FLCN at Ser62 downstream of insulin/mTORC2, and this phosphorylation inhibits RagC GAP activity, establishing FLCN as a convergence point for growth factor and amino acid signaling toward mTORC1.","evidence":"AKT1 kinase assay, Ser62 mutants, lysosomal fractionation with RagD mutants, mTORC1 activity and tumor growth assays","pmids":["37083230"],"confidence":"Medium","gaps":["Whether Ser62 phosphorylation affects FLCN conformation or Rag binding directly not structurally resolved","In vivo physiological significance beyond tumor xenografts not tested","Single lab finding awaiting independent replication"]},{"year":null,"claim":"How FLCN's multiple regulatory inputs (ULK1 phosphorylation, AKT1 phosphorylation, GABARAP sequestration, FNIP2 degradation) are integrated in real time to calibrate RagC/D activity in different physiological contexts remains unresolved, as does the relative contribution of FLCN's Rab11A-dependent vesicular trafficking function versus its lysosomal GAP activity to tumor suppression.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unified quantitative model integrating all FLCN regulatory inputs","Structural basis of FLCN-Rab11A interaction and its relationship to GAP function unresolved","Whether FLCN has additional enzymatic activities beyond RagC/D GAP unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,5,6]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[4,5]}],"localization":[{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[6,20,21]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,18]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[21,22]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,2,4,5,6,7,32]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[10,11]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[8,9,14]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[13,27]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[6,7,8]}],"complexes":["FLCN-FNIP1 complex","FLCN-FNIP2 complex","FLCN-FNIP2-Rag-Ragulator complex"],"partners":["FNIP1","FNIP2","GABARAP","RRAGA","RRAGC","RAB11A","PRKAA1","TARDBP"],"other_free_text":[]},"mechanistic_narrative":"FLCN (folliculin) is a tumor suppressor that functions at the intersection of amino acid sensing, growth factor signaling, lysosomal homeostasis, and mitochondrial metabolism. FLCN heterodimerizes with FNIP1 or FNIP2 through their Longin domains to form a GTPase-activating protein (GAP) for RagC/D GTPases, using an arginine finger (Arg164) to catalyze GTP hydrolysis on RagC/D; this activity is required for mTORC1-dependent cytoplasmic retention of transcription factors TFEB and TFE3, while leaving canonical mTORC1 substrates (S6K, 4E-BP1) largely unaffected [PMID:31704029, PMID:36103527, PMID:27913603]. Loss of FLCN causes constitutive nuclear TFE3/TFEB accumulation, driving PGC-1α/β-dependent mitochondrial biogenesis, AMPK hyperactivation, glycogenesis, and pro-inflammatory cytokine expression across multiple tissues [PMID:21209915, PMID:23150719, PMID:27151976, PMID:30917316, PMID:32049013]. FLCN is recruited to lysosomes in a GATOR1-dependent manner by sensing RagA/B-GDP, is phosphorylated by mTOR, AKT1 (at Ser62), and ULK1, and is sequestered away from its Rag substrates by GABARAP during autophagy, providing multiple layers of regulation that integrate nutrient availability, insulin signaling, and autophagic flux [PMID:29848618, PMID:37083230, PMID:25126726, PMID:34597140]."},"prefetch_data":{"uniprot":{"accession":"Q8NFG4","full_name":"Folliculin","aliases":["BHD skin lesion fibrofolliculoma protein","Birt-Hogg-Dube syndrome protein"],"length_aa":579,"mass_kda":64.5,"function":"Multi-functional protein, involved in both the cellular response to amino acid availability and in the regulation of glycolysis (PubMed:17028174, PubMed:18663353, PubMed:21209915, PubMed:24081491, PubMed:24095279, PubMed:31672913, PubMed:31704029, PubMed:32612235, PubMed:34381247, PubMed:36103527, PubMed:37079666). GTPase-activating protein that plays a key role in the cellular response to amino acid availability through regulation of the non-canonical mTORC1 signaling cascade controlling the MiT/TFE factors TFEB and TFE3 (PubMed:17028174, PubMed:18663353, PubMed:21209915, PubMed:24081491, PubMed:24095279, PubMed:24448649, PubMed:31672913, PubMed:31704029, PubMed:32612235, PubMed:36103527, PubMed:37079666). Activates mTORC1 by acting as a GTPase-activating protein: specifically stimulates GTP hydrolysis by RagC/RRAGC or RagD/RRAGD, promoting the conversion to the GDP-bound state of RagC/RRAGC or RagD/RRAGD, and thereby activating the kinase activity of mTORC1 (PubMed:24095279, PubMed:31672913, PubMed:31704029, PubMed:32612235, PubMed:37079666). The GTPase-activating activity is inhibited during starvation and activated in presence of nutrients (PubMed:31672913, PubMed:32612235). Acts as a key component for non-canonical mTORC1-dependent control of the MiT/TFE factors TFEB and TFE3, while it is not involved in mTORC1-dependent phosphorylation of canonical RPS6KB1/S6K1 and EIF4EBP1/4E-BP1 (PubMed:21209915, PubMed:24081491, PubMed:31672913, PubMed:32612235). In low-amino acid conditions, the lysosomal folliculin complex (LFC) is formed on the membrane of lysosomes, which inhibits the GTPase-activating activity of FLCN, inactivates mTORC1 and maximizes nuclear translocation of TFEB and TFE3 (PubMed:31672913). Upon amino acid restimulation, RagA/RRAGA (or RagB/RRAGB) nucleotide exchange promotes disassembly of the LFC complex and liberates the GTPase-activating activity of FLCN, leading to activation of mTORC1 and subsequent cytoplasmic retention of TFEB and TFE3 (PubMed:31672913). Indirectly acts as a positive regulator of Wnt signaling by promoting mTOR-dependent cytoplasmic retention of MiT/TFE factor TFE3 (PubMed:31272105). Required for the exit of hematopoietic stem cell from pluripotency by promoting mTOR-dependent cytoplasmic retention of TFE3, thereby increasing Wnt signaling (PubMed:30733432). Acts as an inhibitor of browning of adipose tissue by regulating mTOR-dependent cytoplasmic retention of TFE3 (By similarity). Involved in the control of embryonic stem cells differentiation; together with LAMTOR1 it is necessary to recruit and activate RagC/RRAGC and RagD/RRAGD at the lysosomes, and to induce exit of embryonic stem cells from pluripotency via non-canonical, mTOR-independent TFE3 inactivation (By similarity). In response to flow stress, regulates STK11/LKB1 accumulation and mTORC1 activation through primary cilia: may act by recruiting STK11/LKB1 to primary cilia for activation of AMPK resided at basal bodies, causing mTORC1 down-regulation (PubMed:27072130). Together with FNIP1 and/or FNIP2, regulates autophagy: following phosphorylation by ULK1, interacts with GABARAP and promotes autophagy (PubMed:25126726). Required for starvation-induced perinuclear clustering of lysosomes by promoting association of RILP with its effector RAB34 (PubMed:27113757). Regulates glycolysis by binding to lactate dehydrogenase LDHA, acting as an uncompetitive inhibitor (PubMed:34381247)","subcellular_location":"Lysosome membrane; Cytoplasm, cytosol; Cell projection, cilium; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cytoplasm, cytoskeleton, spindle; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8NFG4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FLCN","classification":"Not Classified","n_dependent_lines":117,"n_total_lines":1208,"dependency_fraction":0.09685430463576158},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FLCN","total_profiled":1310},"omim":[{"mim_id":"620459","title":"BIRT-HOGG-DUBE SYNDROME 2; BHD2","url":"https://www.omim.org/entry/620459"},{"mim_id":"618319","title":"PR DOMAIN-CONTAINING PROTEIN 10; PRDM10","url":"https://www.omim.org/entry/618319"},{"mim_id":"612768","title":"FOLLICULIN-INTERACTING PROTEIN 2; FNIP2","url":"https://www.omim.org/entry/612768"},{"mim_id":"610594","title":"FOLLICULIN-INTERACTING PROTEIN 1; FNIP1","url":"https://www.omim.org/entry/610594"},{"mim_id":"607273","title":"FOLLICULIN; FLCN","url":"https://www.omim.org/entry/607273"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/FLCN"},"hgnc":{"alias_symbol":["BHD","MGC17998","MGC23445","DENND8B"],"prev_symbol":[]},"alphafold":{"accession":"Q8NFG4","domains":[{"cath_id":"-","chopping":"4-28_85-222_241-269","consensus_level":"high","plddt":91.2451,"start":4,"end":269},{"cath_id":"3.40.50.12430","chopping":"350-446_459-478","consensus_level":"high","plddt":91.488,"start":350,"end":478},{"cath_id":"1.10.10.1730","chopping":"498-571","consensus_level":"high","plddt":90.2408,"start":498,"end":571}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8NFG4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8NFG4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8NFG4-F1-predicted_aligned_error_v6.png","plddt_mean":78.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FLCN","jax_strain_url":"https://www.jax.org/strain/search?query=FLCN"},"sequence":{"accession":"Q8NFG4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8NFG4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8NFG4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8NFG4"}},"corpus_meta":[{"pmid":"17028174","id":"PMC_17028174","title":"Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17028174","citation_count":395,"is_preprint":false},{"pmid":"18234728","id":"PMC_18234728","title":"BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports.","date":"2008","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18234728","citation_count":358,"is_preprint":false},{"pmid":"15852235","id":"PMC_15852235","title":"Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome.","date":"2005","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15852235","citation_count":304,"is_preprint":false},{"pmid":"19850877","id":"PMC_19850877","title":"Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19850877","citation_count":191,"is_preprint":false},{"pmid":"15956655","id":"PMC_15956655","title":"High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors.","date":"2005","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/15956655","citation_count":182,"is_preprint":false},{"pmid":"21209915","id":"PMC_21209915","title":"Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21209915","citation_count":142,"is_preprint":false},{"pmid":"28970150","id":"PMC_28970150","title":"FLCN: The causative gene for Birt-Hogg-Dubé syndrome.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/28970150","citation_count":133,"is_preprint":false},{"pmid":"22146830","id":"PMC_22146830","title":"Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families.","date":"2011","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22146830","citation_count":126,"is_preprint":false},{"pmid":"14532326","id":"PMC_14532326","title":"A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog.","date":"2003","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14532326","citation_count":120,"is_preprint":false},{"pmid":"18974783","id":"PMC_18974783","title":"Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18974783","citation_count":113,"is_preprint":false},{"pmid":"27913603","id":"PMC_27913603","title":"The tumor suppressor FLCN mediates an alternate mTOR pathway to regulate browning of adipose tissue.","date":"2016","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/27913603","citation_count":110,"is_preprint":false},{"pmid":"31704029","id":"PMC_31704029","title":"Cryo-EM Structure of the Human FLCN-FNIP2-Rag-Ragulator Complex.","date":"2019","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/31704029","citation_count":105,"is_preprint":false},{"pmid":"34597140","id":"PMC_34597140","title":"GABARAP sequesters the FLCN-FNIP tumor suppressor complex to couple autophagy with lysosomal biogenesis.","date":"2021","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/34597140","citation_count":105,"is_preprint":false},{"pmid":"15657874","id":"PMC_15657874","title":"A 4-bp deletion in the Birt-Hogg-Dubé gene (FLCN) causes dominantly inherited spontaneous pneumothorax.","date":"2005","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15657874","citation_count":97,"is_preprint":false},{"pmid":"30917316","id":"PMC_30917316","title":"The Transcription Factors TFEB and TFE3 Link the FLCN-AMPK Signaling Axis to Innate Immune Response and Pathogen Resistance.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30917316","citation_count":94,"is_preprint":false},{"pmid":"12907635","id":"PMC_12907635","title":"Inactivation of BHD in sporadic renal tumors.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12907635","citation_count":92,"is_preprint":false},{"pmid":"27151976","id":"PMC_27151976","title":"Chronic AMPK activation via loss of FLCN induces functional beige adipose tissue through PGC-1α/ERRα.","date":"2016","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/27151976","citation_count":90,"is_preprint":false},{"pmid":"19802896","id":"PMC_19802896","title":"A new locus-specific database (LSDB) for mutations in the folliculin (FLCN) gene.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/19802896","citation_count":88,"is_preprint":false},{"pmid":"23150719","id":"PMC_23150719","title":"Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN.","date":"2012","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/23150719","citation_count":77,"is_preprint":false},{"pmid":"20522427","id":"PMC_20522427","title":"Investigation of the Birt-Hogg-Dube tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer.","date":"2010","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20522427","citation_count":73,"is_preprint":false},{"pmid":"20573232","id":"PMC_20573232","title":"Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.","date":"2010","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20573232","citation_count":73,"is_preprint":false},{"pmid":"14769940","id":"PMC_14769940","title":"A germ-line insertion in the Birt-Hogg-Dubé (BHD) gene gives rise to the Nihon rat model of inherited renal cancer.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/14769940","citation_count":69,"is_preprint":false},{"pmid":"18505456","id":"PMC_18505456","title":"Mutation analysis of the FLCN gene in Chinese patients with sporadic and familial isolated primary spontaneous pneumothorax.","date":"2008","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18505456","citation_count":65,"is_preprint":false},{"pmid":"17124507","id":"PMC_17124507","title":"Novel mutations in the BHD gene and absence of loss of heterozygosity in fibrofolliculomas of Birt-Hogg-Dubé patients.","date":"2006","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17124507","citation_count":64,"is_preprint":false},{"pmid":"25126726","id":"PMC_25126726","title":"FLCN, a novel autophagy component, interacts with GABARAP and is regulated by ULK1 phosphorylation.","date":"2014","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/25126726","citation_count":62,"is_preprint":false},{"pmid":"14627671","id":"PMC_14627671","title":"Analysis of the Birt-Hogg-Dubé (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer.","date":"2003","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14627671","citation_count":58,"is_preprint":false},{"pmid":"29848618","id":"PMC_29848618","title":"GATOR1-dependent recruitment of FLCN-FNIP to lysosomes coordinates Rag GTPase heterodimer nucleotide status in response to amino acids.","date":"2018","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29848618","citation_count":57,"is_preprint":false},{"pmid":"17133269","id":"PMC_17133269","title":"Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma.","date":"2006","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17133269","citation_count":57,"is_preprint":false},{"pmid":"31404503","id":"PMC_31404503","title":"AMPK promotes induction of the tumor suppressor FLCN through activation of TFEB independently of mTOR.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31404503","citation_count":56,"is_preprint":false},{"pmid":"18794106","id":"PMC_18794106","title":"Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18794106","citation_count":51,"is_preprint":false},{"pmid":"24908670","id":"PMC_24908670","title":"Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24908670","citation_count":50,"is_preprint":false},{"pmid":"21412933","id":"PMC_21412933","title":"Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dubé syndrome.","date":"2011","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21412933","citation_count":47,"is_preprint":false},{"pmid":"26439621","id":"PMC_26439621","title":"FLCN and AMPK Confer Resistance to Hyperosmotic Stress via Remodeling of Glycogen Stores.","date":"2015","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26439621","citation_count":46,"is_preprint":false},{"pmid":"16636660","id":"PMC_16636660","title":"The Drosophila homolog of the human tumor suppressor gene BHD interacts with the JAK-STAT and Dpp signaling pathways in regulating male germline stem cell maintenance.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16636660","citation_count":43,"is_preprint":false},{"pmid":"28363698","id":"PMC_28363698","title":"Dihydromyricetin prevents obesity-induced slow-twitch-fiber reduction partially via FLCN/FNIP1/AMPK pathway.","date":"2017","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/28363698","citation_count":36,"is_preprint":false},{"pmid":"20618353","id":"PMC_20618353","title":"Constitutional FLCN mutations in patients with suspected Birt-Hogg-Dubé syndrome ascertained for non-cutaneous manifestations.","date":"2011","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20618353","citation_count":34,"is_preprint":false},{"pmid":"21538689","id":"PMC_21538689","title":"Birt Hogg-Dubé syndrome-associated FLCN mutations disrupt protein stability.","date":"2011","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/21538689","citation_count":33,"is_preprint":false},{"pmid":"28981362","id":"PMC_28981362","title":"The ABCs of BHD: An In-Depth Review of Birt-Hogg-Dubé Syndrome.","date":"2017","source":"AJR. American journal of roentgenology","url":"https://pubmed.ncbi.nlm.nih.gov/28981362","citation_count":31,"is_preprint":false},{"pmid":"36103527","id":"PMC_36103527","title":"Structural basis for FLCN RagC GAP activation in MiT-TFE substrate-selective mTORC1 regulation.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36103527","citation_count":29,"is_preprint":false},{"pmid":"16447066","id":"PMC_16447066","title":"Natural history of the Nihon (Bhd gene mutant) rat, a novel model for human Birt-Hogg-Dubé syndrome.","date":"2006","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16447066","citation_count":25,"is_preprint":false},{"pmid":"26083655","id":"PMC_26083655","title":"Disruption of tubular Flcn expression as a mouse model for renal tumor induction.","date":"2015","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/26083655","citation_count":22,"is_preprint":false},{"pmid":"19695222","id":"PMC_19695222","title":"Regulation of folliculin (the BHD gene product) phosphorylation by Tsc2-mTOR pathway.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19695222","citation_count":22,"is_preprint":false},{"pmid":"21794948","id":"PMC_21794948","title":"Familial multiple discoid fibromas: a look-alike of Birt-Hogg-Dubé syndrome not linked to the FLCN locus.","date":"2011","source":"Journal of the American Academy of Dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/21794948","citation_count":22,"is_preprint":false},{"pmid":"33298956","id":"PMC_33298956","title":"Blood and lymphatic systems are segregated by the FLCN tumor suppressor.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33298956","citation_count":21,"is_preprint":false},{"pmid":"18573707","id":"PMC_18573707","title":"Birt-Hogg-Dubé (BHD) syndrome: report of two novel germline mutations in the folliculin (FLCN) gene.","date":"2008","source":"European journal of dermatology : EJD","url":"https://pubmed.ncbi.nlm.nih.gov/18573707","citation_count":21,"is_preprint":false},{"pmid":"27280402","id":"PMC_27280402","title":"FLCN Maintains the Leucine Level in Lysosome to Stimulate mTORC1.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27280402","citation_count":20,"is_preprint":false},{"pmid":"31272105","id":"PMC_31272105","title":"Loss of FLCN inhibits canonical WNT signaling via TFE3.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31272105","citation_count":18,"is_preprint":false},{"pmid":"28007907","id":"PMC_28007907","title":"H255Y and K508R missense mutations in tumour suppressor folliculin (FLCN) promote kidney cell proliferation.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28007907","citation_count":18,"is_preprint":false},{"pmid":"33459596","id":"PMC_33459596","title":"Loss of FLCN-FNIP1/2 induces a non-canonical interferon response in human renal tubular epithelial cells.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/33459596","citation_count":18,"is_preprint":false},{"pmid":"32049013","id":"PMC_32049013","title":"A FLCN-TFE3 Feedback Loop Prevents Excessive Glycogenesis and Phagocyte Activation by Regulating Lysosome Activity.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32049013","citation_count":18,"is_preprint":false},{"pmid":"22209521","id":"PMC_22209521","title":"Activation of AMP-activated protein kinase by MAPO1 and FLCN induces apoptosis triggered by alkylated base mismatch in DNA.","date":"2011","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/22209521","citation_count":18,"is_preprint":false},{"pmid":"23264078","id":"PMC_23264078","title":"A de novo FLCN mutation in a patient with spontaneous pneumothorax and renal cancer; a clinical and molecular evaluation.","date":"2013","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23264078","citation_count":18,"is_preprint":false},{"pmid":"36440963","id":"PMC_36440963","title":"PRDM10 directs FLCN expression in a novel disorder overlapping with Birt-Hogg-Dubé syndrome and familial lipomatosis.","date":"2023","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36440963","citation_count":17,"is_preprint":false},{"pmid":"34267338","id":"PMC_34267338","title":"A systematic review assessing the existence of pneumothorax-only variants of FLCN. Implications for lifelong surveillance of renal tumours.","date":"2021","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/34267338","citation_count":17,"is_preprint":false},{"pmid":"25807935","id":"PMC_25807935","title":"FLCN intragenic deletions in Chinese familial primary spontaneous pneumothorax.","date":"2015","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/25807935","citation_count":17,"is_preprint":false},{"pmid":"22446046","id":"PMC_22446046","title":"Novel in-frame deletion mutation in FLCN gene in a Korean family with recurrent primary spontaneous pneumothorax.","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/22446046","citation_count":16,"is_preprint":false},{"pmid":"15579036","id":"PMC_15579036","title":"Natural history of the Nihon rat model of BHD.","date":"2004","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15579036","citation_count":16,"is_preprint":false},{"pmid":"29767721","id":"PMC_29767721","title":"BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes.","date":"2018","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29767721","citation_count":16,"is_preprint":false},{"pmid":"26516189","id":"PMC_26516189","title":"Folliculin, a tumor suppressor associated with Birt-Hogg-Dubé (BHD) syndrome, is a novel modifier of TDP-43 cytoplasmic translocation and aggregation.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26516189","citation_count":16,"is_preprint":false},{"pmid":"27258496","id":"PMC_27258496","title":"Case Report of Birt-Hogg-Dubé Syndrome: Germline Mutations of FLCN Detected in Patients With Renal Cancer and Thyroid Cancer.","date":"2016","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27258496","citation_count":16,"is_preprint":false},{"pmid":"31615547","id":"PMC_31615547","title":"Genotypic characteristics of Chinese patients with BHD syndrome and functional analysis of FLCN variants.","date":"2019","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/31615547","citation_count":15,"is_preprint":false},{"pmid":"37182269","id":"PMC_37182269","title":"Comparative analyses define differences between BHD-associated renal tumour and sporadic chromophobe renal cell carcinoma.","date":"2023","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/37182269","citation_count":15,"is_preprint":false},{"pmid":"27734835","id":"PMC_27734835","title":"Genetic screening of the FLCN gene identify six novel variants and a Danish founder mutation.","date":"2016","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27734835","citation_count":15,"is_preprint":false},{"pmid":"28039480","id":"PMC_28039480","title":"Nutrient-induced FNIP degradation by SCFβ-TRCP regulates FLCN complex localization and promotes renal cancer progression.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28039480","citation_count":14,"is_preprint":false},{"pmid":"28623476","id":"PMC_28623476","title":"Early onset renal cell carcinoma in an adolescent girl with germline FLCN exon 5 deletion.","date":"2018","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28623476","citation_count":14,"is_preprint":false},{"pmid":"27633572","id":"PMC_27633572","title":"Bilateral renal tumors in an adult man with Smith-Magenis syndrome: The role of the FLCN gene.","date":"2016","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27633572","citation_count":14,"is_preprint":false},{"pmid":"26418749","id":"PMC_26418749","title":"Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26418749","citation_count":13,"is_preprint":false},{"pmid":"21496834","id":"PMC_21496834","title":"The impact of germline BHD mutation on histological concordance and clinical treatment of patients with bilateral renal masses and known unilateral oncocytoma.","date":"2011","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/21496834","citation_count":13,"is_preprint":false},{"pmid":"29357828","id":"PMC_29357828","title":"Birt-Hogg-Dubé syndrome in two Chinese families with mutations in the FLCN gene.","date":"2018","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29357828","citation_count":12,"is_preprint":false},{"pmid":"36935552","id":"PMC_36935552","title":"Germline- and Somatic-Inactivating FLCN Variants in Parathyroid Cancer and Atypical Parathyroid Tumors.","date":"2023","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/36935552","citation_count":11,"is_preprint":false},{"pmid":"28499369","id":"PMC_28499369","title":"Characterization of a splice-site mutation in the tumor suppressor gene FLCN associated with renal cancer.","date":"2017","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28499369","citation_count":11,"is_preprint":false},{"pmid":"29720200","id":"PMC_29720200","title":"Splice-site mutation causing partial retention of intron in the FLCN gene in Birt-Hogg-Dubé syndrome: a case report.","date":"2018","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/29720200","citation_count":11,"is_preprint":false},{"pmid":"30446510","id":"PMC_30446510","title":"FLCN is a novel Rab11A-interacting protein that is involved in the Rab11A-mediated recycling transport.","date":"2018","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/30446510","citation_count":10,"is_preprint":false},{"pmid":"16369488","id":"PMC_16369488","title":"Transgenic rescue from embryonic lethality and renal carcinogenesis in the Nihon rat model by introduction of a wild-type Bhd gene.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16369488","citation_count":10,"is_preprint":false},{"pmid":"22211584","id":"PMC_22211584","title":"FLCN gene-mutated renal cell neoplasms: mother and daughter cases with a novel germline mutation.","date":"2011","source":"International journal of urology : official journal of the Japanese Urological Association","url":"https://pubmed.ncbi.nlm.nih.gov/22211584","citation_count":10,"is_preprint":false},{"pmid":"34711912","id":"PMC_34711912","title":"Loss of hepatic Flcn protects against fibrosis and inflammation by activating autophagy pathways.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34711912","citation_count":9,"is_preprint":false},{"pmid":"18219524","id":"PMC_18219524","title":"Second hits in the FLCN gene in a hereditary renal cancer syndrome in dogs.","date":"2008","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/18219524","citation_count":9,"is_preprint":false},{"pmid":"19733897","id":"PMC_19733897","title":"Novel intronic germline FLCN gene mutation in a patient with multiple ipsilateral renal neoplasms.","date":"2009","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19733897","citation_count":9,"is_preprint":false},{"pmid":"19387735","id":"PMC_19387735","title":"Loss of heterozygosity at the FLCN locus in early renal cystic lesions in dogs with renal cystadenocarcinoma and nodular dermatofibrosis.","date":"2009","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/19387735","citation_count":9,"is_preprint":false},{"pmid":"37083230","id":"PMC_37083230","title":"Role of FLCN Phosphorylation in Insulin-Mediated mTORC1 Activation and Tumorigenesis.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37083230","citation_count":8,"is_preprint":false},{"pmid":"28222720","id":"PMC_28222720","title":"Birt-Hogg-Dubé syndrome: a literature review and case study of a Chinese woman presenting a novel FLCN mutation.","date":"2017","source":"BMC pulmonary medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28222720","citation_count":8,"is_preprint":false},{"pmid":"32184379","id":"PMC_32184379","title":"FLCN-regulated miRNAs suppressed reparative response in cells and pulmonary lesions of Birt-Hogg-Dubé syndrome.","date":"2020","source":"Thorax","url":"https://pubmed.ncbi.nlm.nih.gov/32184379","citation_count":8,"is_preprint":false},{"pmid":"32934076","id":"PMC_32934076","title":"Quantitative genetic screening reveals a Ragulator-FLCN feedback loop that regulates the mTORC1 pathway.","date":"2020","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/32934076","citation_count":8,"is_preprint":false},{"pmid":"37170274","id":"PMC_37170274","title":"Exons 1-3 deletion in FLCN is associated with increased risk of pneumothorax in Chinese patients with Birt-Hogg-Dubé syndrome.","date":"2023","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/37170274","citation_count":8,"is_preprint":false},{"pmid":"23416984","id":"PMC_23416984","title":"Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23416984","citation_count":7,"is_preprint":false},{"pmid":"35176117","id":"PMC_35176117","title":"A retrospective two centre study of Birt-Hogg-Dubé syndrome reveals a pathogenic founder mutation in FLCN in the Swedish population.","date":"2022","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/35176117","citation_count":7,"is_preprint":false},{"pmid":"18036795","id":"PMC_18036795","title":"Postoperative fibromatosis-type fibromas in the Bhd gene mutant (Nihon) rat.","date":"2007","source":"Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie","url":"https://pubmed.ncbi.nlm.nih.gov/18036795","citation_count":7,"is_preprint":false},{"pmid":"33609526","id":"PMC_33609526","title":"FLCN regulates transferrin receptor 1 transport and iron homeostasis.","date":"2021","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33609526","citation_count":6,"is_preprint":false},{"pmid":"28805452","id":"PMC_28805452","title":"Birt-Hogg-Dube Syndrome with a Novel Mutation in the FLCN Gene.","date":"2017","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/28805452","citation_count":6,"is_preprint":false},{"pmid":"38456787","id":"PMC_38456787","title":"The Prevalence and Radiologic Features of Renal Cancers Associated with FLCN, BAP1, SDH, and MET Germline Mutations.","date":"2024","source":"Radiology. Imaging cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38456787","citation_count":6,"is_preprint":false},{"pmid":"31806376","id":"PMC_31806376","title":"FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31806376","citation_count":6,"is_preprint":false},{"pmid":"36410626","id":"PMC_36410626","title":"Minigene Assay as an Effective Molecular Diagnostic Strategy in Determining the Pathogenicity of Noncanonical Splice-Site Variants in FLCN.","date":"2022","source":"The Journal of molecular diagnostics : JMD","url":"https://pubmed.ncbi.nlm.nih.gov/36410626","citation_count":6,"is_preprint":false},{"pmid":"33927747","id":"PMC_33927747","title":"A Novel FLCN Intragenic Deletion Identified by NGS in a BHDS Family and Literature Review.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33927747","citation_count":6,"is_preprint":false},{"pmid":"26342594","id":"PMC_26342594","title":"Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas.","date":"2016","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26342594","citation_count":6,"is_preprint":false},{"pmid":"39556154","id":"PMC_39556154","title":"Integrated systems pharmacology, molecular docking, and MD simulations investigation elucidating the therapeutic mechanisms of BHD in Alzheimer's disease treatment.","date":"2024","source":"Metabolic brain disease","url":"https://pubmed.ncbi.nlm.nih.gov/39556154","citation_count":6,"is_preprint":false},{"pmid":"30672048","id":"PMC_30672048","title":"Unilateral renal cystadenocarcinoma and nodular dermatofibrosis in a mixed-breed dog carrying a FLCN gene mutation.","date":"2019","source":"Veterinary dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30672048","citation_count":6,"is_preprint":false},{"pmid":"36701047","id":"PMC_36701047","title":"FLCN-Driven Functional Adrenal Cortical Carcinoma with High Mitotic Tumor Grade: Extending the Endocrine Manifestations of Birt-Hogg-Dubé Syndrome.","date":"2023","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/36701047","citation_count":6,"is_preprint":false},{"pmid":"27486260","id":"PMC_27486260","title":"Novel folliculin (FLCN) mutation and familial spontaneous pneumothorax.","date":"2016","source":"QJM : monthly journal of the Association of Physicians","url":"https://pubmed.ncbi.nlm.nih.gov/27486260","citation_count":5,"is_preprint":false},{"pmid":"26603437","id":"PMC_26603437","title":"Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?","date":"2016","source":"Familial cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26603437","citation_count":5,"is_preprint":false},{"pmid":"28069055","id":"PMC_28069055","title":"Novel germline mutations in FLCN gene identified in two Chinese patients with Birt-Hogg-Dubé syndrome.","date":"2017","source":"Chinese journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28069055","citation_count":5,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50698,"output_tokens":8662,"usd":0.141012},"stage2":{"model":"claude-opus-4-6","input_tokens":12504,"output_tokens":3936,"usd":0.24138},"total_usd":0.382392,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"FLCN (folliculin) interacts directly with FNIP1 (folliculin-interacting protein 1), which in turn interacts with AMPK. FNIP1 is phosphorylated by AMPK, and FLCN phosphorylation is regulated by both mTOR (reduced by rapamycin and amino acid starvation) and AMPK signaling, placing FLCN in the AMPK-mTOR nutrient-sensing pathway.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry identification of FNIP1, in vitro phosphorylation assays, AMPK inhibitor/rapamycin treatment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, MS interactome, biochemical phosphorylation assays; foundational paper replicated widely\",\n      \"pmids\": [\"17028174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Homozygous loss of BHD/FLCN causes embryonic lethality at E5.5-E6.5 in mice. Kidney tumors from BHD heterozygous knockout mice and human BHD patients show activation of both mTORC1 and mTORC2, and elevated total AKT protein (without increased mRNA), suggesting FLCN regulates AKT post-translationally or post-transcriptionally.\",\n      \"method\": \"Mouse knockout model (homozygous and heterozygous), immunoblotting for mTORC1/mTORC2 substrates, qRT-PCR, LOH analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular/developmental phenotype plus molecular pathway analysis; replicated in multiple tumor types\",\n      \"pmids\": [\"19850877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Kidney-specific deletion of BHD/FLCN in mice activates the mTOR pathway, and rapamycin treatment suppresses cystogenesis and extends survival, establishing FLCN as a functional upstream negative regulator of mTOR in renal cells.\",\n      \"method\": \"Conditional kidney-specific knockout (Ksp-Cre), rapamycin treatment rescue experiment, histological and biochemical analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined phenotypic rescue by mTOR inhibitor; strong causal pathway evidence\",\n      \"pmids\": [\"18974783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FLCN inactivation causes increased nuclear localization of TFE3 (accompanied by decreased TFE3 phosphorylation), leading to elevated TFE3 transcriptional activity and upregulation of GPNMB expression. This establishes TFE3 nuclear translocation as a downstream consequence of FLCN loss.\",\n      \"method\": \"FLCN knockdown/restoration in renal cancer cells, TFE3 knockdown, immunostaining of TFE3 in cells/mouse kidneys/human tumors, mRNA/protein expression analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (KD, reconstitution, immunostaining in multiple model systems); replicated in subsequent studies\",\n      \"pmids\": [\"21209915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FLCN-FNIP2 functions as a GTPase-activating protein (GAP) for RagC/D GTPases. Cryo-EM structure of the FLCN-FNIP2-Rag-Ragulator complex reveals that FLCN and FNIP2 adopt an extended conformation with Longin domains heterodimerizing and contacting Rag nucleotide-binding domains, while DENN domains interact distally. A conserved arginine on FLCN acts as the catalytic arginine finger for RagC/D GAP activity.\",\n      \"method\": \"Cryo-EM structure determination, biochemical GAP activity assays, mutagenesis of catalytic arginine\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure with biochemical validation and mutagenesis in a single rigorous study\",\n      \"pmids\": [\"31704029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cryo-EM structure of the active FLCN complex (AFC) containing FLCN, FNIP2, SLC38A9 N-terminal tail, RagA(GDP):RagC(GDP·BeFx), and Ragulator reveals that during GAP activation FLCN reorients ~90° relative to the inactive lysosomal complex, breaks contact with RagA, and makes new contacts with RagC that position Arg164 for catalysis. Disruption of AFC-specific FLCN-RagC interfaces eliminates GAP activity and causes nuclear retention of TFE3 without affecting S6K or 4E-BP1 phosphorylation, demonstrating substrate-selective mTORC1 regulation.\",\n      \"method\": \"Cryo-EM structure determination, mutagenesis of interface residues, GAP activity assays, TFE3 localization assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure plus mutagenesis and functional validation; demonstrates mechanistic basis for substrate selectivity\",\n      \"pmids\": [\"36103527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FLCN-FNIP complex is recruited to lysosomes during amino acid starvation in a manner dependent on GATOR1 GAP activity toward RagA/B (which converts RagA/B to GDP-bound state). By binding RagA/B(GDP) and acting as a GAP on RagC/D, the FLCN-FNIP complex coordinates nucleotide status between Rag heterodimer subunits in response to amino acid availability.\",\n      \"method\": \"Lysosomal fractionation, RagA/B nucleotide-loading mutants, GATOR1 knockdown, co-immunoprecipitation\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods defining FLCN lysosomal recruitment mechanism and epistatic relationship with GATOR1\",\n      \"pmids\": [\"29848618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Adipose-specific deletion of FLCN relieves mTOR-dependent cytoplasmic retention of TFE3, leading to nuclear TFE3 and direct induction of PGC-1α/PGC-1β, driving mitochondrial biogenesis and adipose browning. This FLCN-mTOR-TFE3-PGC-1β pathway is separable from canonical TSC-mTOR-S6K signaling and is driven by RagC/D.\",\n      \"method\": \"Adipose-specific conditional KO, TFE3 and PGC-1β co-deletion rescue, inducible PGC-1β expression, amino acid sensitivity assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis via multiple conditional KO combinations with defined molecular and physiological readouts\",\n      \"pmids\": [\"27913603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Adipose-specific loss of FLCN causes chronic hyperactivation of AMPK, which in turn induces and activates PGC-1α and ERRα, driving mitochondrial biogenesis and browning of white adipose tissue through the AMPK/PGC-1α/ERRα axis.\",\n      \"method\": \"Adipose-specific FLCN knockout mouse, AMPK activity assays, gene expression analysis, metabolic phenotyping\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined molecular pathway; complementary to other adipose FLCN study from same year\",\n      \"pmids\": [\"27151976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Muscle-targeted FLCN knockout leads to increased mitochondrial biogenesis and oxidative phosphorylation in a PGC-1α (PPARGC1A)-dependent manner. Reconstitution of FLCN-null kidney cancer cells with wild-type FLCN suppresses mitochondrial metabolism and PGC-1α expression, establishing FLCN as a negative regulator of PGC-1α-driven mitochondrial oxidative metabolism.\",\n      \"method\": \"Conditional muscle/kidney KO mice, PPARGC1A double KO rescue, electron microscopy, oxygen consumption measurement, FLCN reconstitution in null cells\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple conditional KO systems with genetic rescue and in vitro reconstitution\",\n      \"pmids\": [\"23150719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GABARAP (but not LC3) directly binds to a previously unidentified LIR motif in the FLCN/FNIP complex, sequestering it to GABARAP-conjugated membrane compartments during autophagy (CASM, mitophagy, xenophagy). This disrupts FLCN/FNIP GAP function toward RagC/D, resulting in impaired mTOR-dependent phosphorylation of TFEB, thereby activating TFEB/TFE3 to control lysosomal capacity.\",\n      \"method\": \"Co-IP identifying GABARAP-FLCN interaction, LIR motif identification/mutagenesis, GABARAP-specific vs. LC3-specific depletion, TFEB phosphorylation assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct binding identification with LIR motif mutagenesis plus functional GAP activity and phosphorylation readouts\",\n      \"pmids\": [\"34597140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FLCN interacts with GABARAP (autophagy protein), and this interaction is modulated by FNIP1 or FNIP2. ULK1 phosphorylates FLCN at Ser406, Ser537, and Ser542. Loss of FLCN impairs basal autophagic flux; re-expression of FLCN rescues autophagy.\",\n      \"method\": \"Co-IP (FLCN-GABARAP), in vitro ULK1 phosphorylation assay with site identification by mass spectrometry, autophagic flux assays with LC3/SQSTM1\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro phosphorylation with site mapping, reciprocal Co-IP, functional autophagy readouts\",\n      \"pmids\": [\"25126726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"FLCN phosphorylation is regulated downstream of the TSC2-mTORC1 axis: downregulation of tuberin or Rheb expression induces multiple FLCN phosphorylation events. Phosphorylation at Ser62 and Ser302 are differentially regulated by mTORC1-dependent pathways, and FLCN phosphorylation state modulates its complex formation with AMPK.\",\n      \"method\": \"Tuberin/Rheb overexpression/knockdown with immunoblotting for FLCN phospho-sites, co-immunoprecipitation of FLCN-AMPK complex\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct phospho-site analysis with multiple genetic perturbations; single lab, limited orthogonal validation\",\n      \"pmids\": [\"19695222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FLCN and AMPK act upstream of TFEB/TFE3 in the innate immune response independently of mTORC1. Loss of FLCN or pharmacological AMPK activation induces TFEB/TFE3-dependent pro-inflammatory cytokine expression in mammalian macrophages; LPS treatment causes acute AMPK activation accompanied by TFEB nuclear localization.\",\n      \"method\": \"C. elegans FLCN ortholog loss-of-function, mammalian FLCN KO cells, AMPK pharmacological activation, TFEB/TFE3 knockdown, cytokine/reporter assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis across two model organisms plus mammalian cells with multiple orthogonal readouts\",\n      \"pmids\": [\"30917316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In C. elegans, loss of FLCN-1 (FLCN ortholog) increases resistance to hyperosmotic stress via constitutive AMPK-dependent accumulation of glycogen; upon stress, glycogen is degraded to glycerol. This pathway requires glycogen synthase, glycogen phosphorylase, and GPDH enzymes. Glycogen accumulates in kidneys from FLCN-knockout mice and BHD patient renal tumors.\",\n      \"method\": \"C. elegans FLCN-1 loss-of-function, double mutants with AMPK/glycogen metabolism genes (epistasis), mouse kidney fractionation, BHD patient tumor analysis\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in C. elegans with multiple double-mutant rescue experiments; validated in mammalian tissue\",\n      \"pmids\": [\"26439621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The Drosophila BHD homolog (DBHD) is required for male germline stem cell (GSC) maintenance. RNAi-mediated reduction of DBHD suppresses GSC overproliferation caused by overexpression of JAK-STAT ligand (upd) or BMP ligand (dpp), placing DBHD downstream or in parallel of JAK/STAT and Dpp signaling pathways.\",\n      \"method\": \"RNAi knockdown in Drosophila testis, genetic interaction assays with upd/dpp overexpression (epistasis), GSC counting\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in Drosophila ortholog; single organism, defined pathway placement\",\n      \"pmids\": [\"16636660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cardiac-specific loss of FLCN causes severe cardiac hypertrophy with mTORC1 upregulation; rapamycin treatment reduces heart mass. FLCN deficiency reduces phospho-AMPK (T172) and elevates PGC-1α (PPARGC1A), increasing mitochondrial metabolism. Inactivation of PPARGC1A in FLCN-deficient hearts restores phospho-AMPK levels and suppresses mTORC1, establishing a FLCN-PPARGC1A-AMPK-mTORC1 axis in cardiac hypertrophy.\",\n      \"method\": \"Cardiac-specific conditional KO, PPARGC1A double KO rescue, rapamycin treatment, AMPK activity assays, ATP level measurement\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple conditional KO and rescue experiments establishing epistasis, with pharmacological validation\",\n      \"pmids\": [\"24908670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FLCN reconstitution in FLCN-null renal cells suppresses tumor formation in nude mice and upregulates TGF-β signaling components (TGFB2, INHBA/activin A, THBS1, SMAD3). Activin A (INHBA homodimer) completely suppresses anchorage-independent growth of FLCN-null cells, identifying TGF-β/activin signaling as a downstream effector of FLCN tumor suppression.\",\n      \"method\": \"Stable FLCN re-expression in null cell line, nude mouse xenograft, gene expression profiling, anchorage-independent growth assay\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reconstitution plus functional assay; single lab, pathway placement via differential expression and functional rescue\",\n      \"pmids\": [\"20573232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FLCN directly interacts with TDP-43 via FLCN amino acids 202-299 binding to the RRM domains of TDP-43. Both exogenous and endogenous FLCN promote TDP-43 cytoplasmic translocation, protein aggregation, and stress granule formation.\",\n      \"method\": \"Co-immunoprecipitation, domain mapping by deletion constructs, FLCN knockdown and overexpression with TDP-43 localization assays, stress granule imaging\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — direct binding with domain mapping and functional localization assay; single lab\",\n      \"pmids\": [\"26516189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FLCN, MAPO1 (FNIP2), and AMPK form a complex required for apoptosis induced by O6-methylguanine alkylation. After MNU treatment, AMPKα phosphorylation occurs in an MLH1-dependent manner and requires both MAPO1 and FLCN expression; AICAR-induced AMPK activation is also MAPO1- and FLCN-dependent.\",\n      \"method\": \"siRNA knockdown of FLCN/MAPO1/AMPK, sub-G1 DNA content assay, AICAR/MNU treatment, mitochondrial membrane potential assay\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function plus pharmacological activation with defined molecular readouts; single lab\",\n      \"pmids\": [\"22209521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FNIP2 protein is degraded via β-TRCP/CK1-directed ubiquitination in a nutrition-dependent manner. FNIP2 degradation leads to lysosomal dissociation of FLCN and subsequent lysosomal association of mTOR, promoting renal cancer cell proliferation.\",\n      \"method\": \"Ubiquitination assays, β-TRCP co-IP, lysosomal fractionation, CK1 inhibition\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical ubiquitination assay with fractionation showing functional consequence; single lab\",\n      \"pmids\": [\"28039480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FLCN binds to Rab11A through its C-terminal DENN-like domain and promotes loading of the amino acid transporter PAT1 onto Rab11A-positive recycling vesicles, maintaining PAT1 on the plasma membrane rather than at lysosomes, thereby sustaining lysosomal amino acid signaling and mTORC1 activity.\",\n      \"method\": \"Co-IP of FLCN-Rab11A, domain mapping, in vitro GEF assay (negative result), PAT1 localization by imaging, mTORC1 activity assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding with domain mapping, in vitro assay, and functional localization consequence; single lab\",\n      \"pmids\": [\"30446510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FLCN promotes Rab11A binding to transferrin receptor 1 (TfR1) to facilitate TfR1 recycling transport. Loss of FLCN attenuates Rab11A-TfR1 interaction, delays TfR1 recycling, causes iron deficiency, and induces HIF activity. Iron supplementation reverses HIF activation in FLCN-deficient cells; dietary iron rescues BHD phenotype in Drosophila.\",\n      \"method\": \"Co-IP (FLCN-Rab11A-TfR1), FLCN KO cells, TfR1 recycling assay, HIF reporter, Drosophila dietary rescue\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, functional recycling assay, in vivo Drosophila rescue; single lab\",\n      \"pmids\": [\"33609526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FLCN maintains the leucine level within lysosomes by inhibiting accumulation of the amino acid transporter PAT1 on the lysosome surface, thereby sustaining lysosomal leucine as a signal to activate mTORC1. Supplementation with high leucine (but not other amino acids) rescues mTORC1 activity lost upon FLCN suppression.\",\n      \"method\": \"FLCN knockdown/overexpression in HEK293, lysosomal leucine measurement, PAT1 localization assays, amino acid rescue experiments\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — amino acid-specific rescue plus transporter localization analysis; single lab\",\n      \"pmids\": [\"27280402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"AMPK promotes expression of FLCN through activation of TFEB (independently of mTOR), identifying a novel AMPK-TFEB-FLCN axis. AMPK-induced FLCN expression is abolished in MEFs lacking TFEB/TFE3, and mutation of the putative TFEB-binding site in the FLCN promoter reduces promoter activity. This axis is conserved in zebrafish.\",\n      \"method\": \"Whole-genome transcriptome profiling, TFEB/TFE3 double KO MEFs, promoter-luciferase reporter assay with TFEB site mutation, zebrafish AMPK KO model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transcriptomics plus promoter mutagenesis and genetic KO validation; single lab\",\n      \"pmids\": [\"31404503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FLCN loss in hematopoietic cells activates TFE3, which stimulates glycogenesis by transcriptionally upregulating glycogenesis genes (Gys1, Gyg). TFE3 also transcriptionally activates FLCN expression (feedback loop). Tfe3 deletion in FLCN-KO mice reduces phagocyte expansion and LSD-like phenotypes, establishing a FLCN-TFE3 rheostat controlling lysosome activity and glycogenesis.\",\n      \"method\": \"Hematopoietic-lineage conditional Flcn KO, Tfe3/Flcn double KO rescue, ChIP/transcriptional target analysis, metabolite analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic double-KO epistasis with defined molecular (transcriptional targets) and cellular phenotypes\",\n      \"pmids\": [\"32049013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Genetic deficiency of FLCN in mice leads to nuclear translocation of TFE3 in venous endothelial cells, which drives ectopic expression of Prox1 (master transcription factor for lymphatic specification) by binding a regulatory element in the Prox1 gene, causing misconnection of blood and lymphatic vessels.\",\n      \"method\": \"Endothelial-specific Flcn KO mouse, TFE3 ChIP on Prox1 regulatory element, Prox1 expression analysis, vascular phenotype characterization\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with ChIP demonstrating direct TFE3 binding to Prox1 regulatory element; defined vascular phenotype\",\n      \"pmids\": [\"33298956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss of FLCN in human renal tubular epithelial cells activates TFE3 (upregulating RRAGD and GPNMB) without modifying bulk mTORC1 activity, and independently induces STAT1/STAT2-dependent interferon response genes via increased STAT2 chromatin recruitment, slowing cellular proliferation.\",\n      \"method\": \"CRISPR KO of FLCN/FNIP1/FNIP2 in RPTEC/TERT1 cells, RNA-seq, ChIP-seq (STAT2), TFE3 nuclear localization, proliferation assays\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO with ChIP-seq demonstrating direct STAT2 chromatin recruitment; multiple orthogonal methods\",\n      \"pmids\": [\"33459596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss of FLCN in mouse embryonic fibroblasts and lung fibroblasts inhibits canonical WNT signaling via TFE3: FLCN deficiency decreases Wnt2/Wnt7b expression and TCF/LEF activity; silencing TFE3 completely reverses this phenotype whereas constitutively active β-catenin only partially rescues it.\",\n      \"method\": \"Flcn KO in MEFs and MRC-5 cells, RNA-seq, TCF/LEF reporter assay, TFE3 siRNA rescue, active β-catenin rescue\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with TFE3 rescue epistasis establishing pathway; single lab\",\n      \"pmids\": [\"31272105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"FLCN H255Y missense mutation fails to rescue multi-cystic kidney phenotype in Flcn-KO mice, demonstrating loss of tumor suppressor function. The FLCN K508R missense mutation partially rescues but can also cause cystic kidneys and cardiac hypertrophy in heterozygous KO mice, suggesting a dominant negative effect on wild-type FLCN function.\",\n      \"method\": \"BAC recombineering transgenic rescue in kidney-specific Flcn KO mice, histological phenotype analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic rescue with defined tissue phenotypes; single lab\",\n      \"pmids\": [\"28007907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Pathogenic FLCN missense and in-frame deletion mutations significantly disrupt the stability of the FLCN protein product, while missense variants that do not impair protein stability also do not impair tumor suppressor activity or intracellular localization, indicating that protein stability is a key determinant of folliculin tumor suppressor function.\",\n      \"method\": \"In vitro protein stability assays, growth suppression assay, intracellular localization by fluorescence microscopy, evolutionary conservation analysis\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays correlating stability with tumor suppressor activity; single lab\",\n      \"pmids\": [\"21538689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A splice-site mutation (c.1177-5_-3delCTC) causes exon 11 skipping in FLCN, producing a truncated protein that is strongly destabilized (reversible by proteasomal and lysosomal degradation inhibitors) and has altered subcellular localization compared to wild-type FLCN.\",\n      \"method\": \"Minigene splicing assay, TALEN-mediated transgenesis in cultured cells, protein stability assays with inhibitors, subcellular localization by immunofluorescence\",\n      \"journal\": \"BMC medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — minigene assay, transgenesis, and biochemical characterization of mutant protein; single lab\",\n      \"pmids\": [\"28499369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FLCN is phosphorylated at Ser62 by AKT1 (downstream of insulin/mTORC2). RagD-specific recruitment of mTORC2-AKT1 to lysosomes is required for insulin-stimulated FLCN phosphorylation. FLCN Ser62 phosphorylation inhibits RagC GTPase activity and is essential for insulin-induced mTORC1 activation, identifying FLCN as a cross-talk node between amino acid and growth factor (insulin) mTORC1 activation pathways.\",\n      \"method\": \"Phosphorylation site identification, AKT1 kinase assays, lysosomal fractionation, RagD mutants, mTORC1 activity assays, in vivo tumor growth assays\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical kinase assay with site mapping and genetic validation; single lab\",\n      \"pmids\": [\"37083230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRDM10 directly binds a regulatory motif in the FLCN promoter to control FLCN mRNA and protein expression. The pathogenic PRDM10 Cys677Tyr variant loses affinity for this FLCN promoter binding motif, abolishing cellular FLCN expression.\",\n      \"method\": \"Promoter binding assay, PRDM10 variant functional analysis, FLCN mRNA/protein quantification in cells overexpressing wild-type vs. mutant PRDM10\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding demonstrated with functional consequence on FLCN expression; single lab\",\n      \"pmids\": [\"36440963\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FLCN (folliculin) is a tumor suppressor that functions as the catalytic subunit of the FLCN-FNIP1/2 heterodimeric GTPase-activating protein (GAP) complex for RagC/D GTPases; during amino acid sufficiency, FLCN-FNIP is recruited to lysosomes via GATOR1-dependent sensing of RagA/B-GDP, where it activates RagC/D to drive Rag heterodimer-dependent mTORC1 activation specifically toward MiT/TFE substrates (TFEB/TFE3), while loss of FLCN causes nuclear TFE3/TFEB accumulation, upregulation of PGC-1α-driven mitochondrial biogenesis, and AMPK hyperactivation; FLCN is itself phosphorylated by mTOR and AKT1 (at Ser62), regulated by AMPK, subject to ULK1-dependent phosphorylation during autophagy, and sequestered by GABARAP to disrupt its GAP function during autophagic flux, placing FLCN at a critical intersection of amino acid sensing, growth factor signaling, lysosomal homeostasis, and mitochondrial metabolism.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"FLCN (folliculin) is a tumor suppressor that functions at the intersection of amino acid sensing, growth factor signaling, lysosomal homeostasis, and mitochondrial metabolism. FLCN heterodimerizes with FNIP1 or FNIP2 through their Longin domains to form a GTPase-activating protein (GAP) for RagC/D GTPases, using an arginine finger (Arg164) to catalyze GTP hydrolysis on RagC/D; this activity is required for mTORC1-dependent cytoplasmic retention of transcription factors TFEB and TFE3, while leaving canonical mTORC1 substrates (S6K, 4E-BP1) largely unaffected [PMID:31704029, PMID:36103527, PMID:27913603]. Loss of FLCN causes constitutive nuclear TFE3/TFEB accumulation, driving PGC-1α/β-dependent mitochondrial biogenesis, AMPK hyperactivation, glycogenesis, and pro-inflammatory cytokine expression across multiple tissues [PMID:21209915, PMID:23150719, PMID:27151976, PMID:30917316, PMID:32049013]. FLCN is recruited to lysosomes in a GATOR1-dependent manner by sensing RagA/B-GDP, is phosphorylated by mTOR, AKT1 (at Ser62), and ULK1, and is sequestered away from its Rag substrates by GABARAP during autophagy, providing multiple layers of regulation that integrate nutrient availability, insulin signaling, and autophagic flux [PMID:29848618, PMID:37083230, PMID:25126726, PMID:34597140].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Identification of FNIP1 as a direct FLCN-binding partner that bridges FLCN to AMPK, and demonstration that FLCN phosphorylation is regulated by both mTOR and AMPK, placed FLCN within the nutrient-sensing signaling network for the first time.\",\n      \"evidence\": \"Co-immunoprecipitation, mass spectrometry identification of FNIP1, phosphorylation assays with rapamycin/AMPK inhibitors in mammalian cells\",\n      \"pmids\": [\"17028174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase directly phosphorylating FLCN not yet identified\", \"Functional consequence of FLCN phosphorylation unknown\", \"Whether FLCN-FNIP complex has enzymatic activity unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Kidney-specific Flcn knockout demonstrated that FLCN is a bona fide upstream negative regulator of mTOR in vivo, with rapamycin rescuing the cystic phenotype, establishing the first causal tissue-level pathway link.\",\n      \"evidence\": \"Conditional kidney-specific KO mice (Ksp-Cre) with rapamycin rescue\",\n      \"pmids\": [\"18974783\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of mTOR activation upon FLCN loss unknown\", \"Whether FLCN acts directly on mTOR or through intermediaries unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Homozygous FLCN loss causes embryonic lethality, and heterozygous tumors show dual mTORC1/mTORC2 activation with elevated AKT protein, revealing that FLCN loss deregulates both mTOR complexes and may stabilize AKT post-translationally.\",\n      \"evidence\": \"BHD knockout mice (homozygous and heterozygous), immunoblotting for mTORC1/mTORC2 substrates, qRT-PCR\",\n      \"pmids\": [\"19850877\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of AKT protein stabilization unknown\", \"Whether mTORC2 activation is a direct or indirect consequence of FLCN loss not determined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Discovery that FLCN loss causes nuclear TFE3 accumulation and transcriptional activation identified the first specific transcription factor target downstream of FLCN, shifting the field beyond generic mTOR activation toward a substrate-selective model.\",\n      \"evidence\": \"FLCN knockdown/reconstitution in renal cancer cells, TFE3 localization in cells/mouse kidneys/human tumors\",\n      \"pmids\": [\"21209915\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking FLCN to TFE3 phosphorylation not known\", \"Whether TFEB is similarly regulated not tested\", \"RagC/D involvement not yet suspected\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Tissue-specific knockouts established FLCN as a negative regulator of PGC-1α-driven mitochondrial biogenesis, linking FLCN tumor suppression to metabolic reprogramming.\",\n      \"evidence\": \"Muscle-specific Flcn KO with PGC-1α double-KO rescue, oxygen consumption measurements, FLCN reconstitution in kidney cancer cells\",\n      \"pmids\": [\"23150719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PGC-1α induction is a direct transcriptional effect of TFE3 or an indirect consequence not resolved\", \"Relative contribution of AMPK vs. TFE3 to PGC-1α induction unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of FLCN-GABARAP interaction and ULK1-mediated phosphorylation of FLCN at Ser406/Ser537/Ser542 linked FLCN directly to the autophagy machinery, and loss of FLCN was shown to impair basal autophagic flux.\",\n      \"evidence\": \"Co-IP of FLCN-GABARAP, in vitro ULK1 kinase assay with mass spectrometry site mapping, autophagic flux assays\",\n      \"pmids\": [\"25126726\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of individual ULK1 phosphorylation sites not determined\", \"How FLCN promotes autophagic flux mechanistically undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Two complementary adipose-specific knockout studies resolved parallel downstream pathways: one showing FLCN restrains TFE3-PGC-1β-driven browning via RagC/D (separable from TSC-S6K signaling), the other showing FLCN restrains AMPK-PGC-1α/ERRα-driven mitochondrial biogenesis, together establishing FLCN as a dual-axis metabolic gatekeeper.\",\n      \"evidence\": \"Adipose-specific Flcn KO with TFE3/PGC-1β double-KO rescue, and separate adipose Flcn KO with AMPK activity assays and metabolic phenotyping\",\n      \"pmids\": [\"27913603\", \"27151976\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the TFE3/RagC and AMPK axes are independent or converge at a single node is unresolved\", \"Relative in vivo contribution of each axis in kidney tumorigenesis unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The discovery that FLCN-FNIP is recruited to lysosomes in a GATOR1-dependent manner by sensing RagA/B-GDP established the molecular logic of how amino acid status is read by FLCN to coordinate Rag heterodimer nucleotide states.\",\n      \"evidence\": \"Lysosomal fractionation, RagA/B nucleotide-loading mutants, GATOR1 knockdown, co-immunoprecipitation\",\n      \"pmids\": [\"29848618\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of FLCN recognition of RagA-GDP not yet determined\", \"Whether other signals besides GATOR1 regulate FLCN lysosomal recruitment unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Cryo-EM structure of the inactive FLCN-FNIP2-Rag-Ragulator complex revealed the catalytic arginine finger mechanism of FLCN GAP activity toward RagC/D, providing the first atomic-level understanding of FLCN's enzymatic function.\",\n      \"evidence\": \"Cryo-EM at near-atomic resolution, mutagenesis of catalytic arginine, in vitro GAP assays\",\n      \"pmids\": [\"31704029\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Complex captured in inactive conformation; the active GAP transition state not yet visualized\", \"Whether FNIP1 and FNIP2 confer different catalytic properties unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"FLCN-AMPK-TFE3 axis was shown to operate in innate immunity independently of mTORC1, with FLCN loss or AMPK activation inducing TFEB/TFE3-dependent pro-inflammatory cytokine expression in macrophages, broadening FLCN's role beyond metabolic sensing to immune regulation.\",\n      \"evidence\": \"C. elegans FLCN ortholog mutants, mammalian FLCN KO macrophages, pharmacological AMPK activation, TFEB/TFE3 knockdown, cytokine assays\",\n      \"pmids\": [\"30917316\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FLCN-dependent immune phenotypes contribute to BHD disease manifestations unknown\", \"Mechanism by which AMPK activates TFEB/TFE3 independently of mTORC1 not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"GABARAP was found to sequester FLCN-FNIP via a LIR motif during autophagy (CASM, mitophagy, xenophagy), explaining how autophagic flux activates TFEB by physically displacing FLCN from its Rag substrates — a key mechanistic link between autophagy and lysosomal biogenesis.\",\n      \"evidence\": \"GABARAP-FLCN co-IP, LIR motif mutagenesis, GABARAP-specific vs. LC3-specific depletion, TFEB phosphorylation assays\",\n      \"pmids\": [\"34597140\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GABARAP-FLCN sequestration occurs on specific membrane compartments in vivo not fully mapped\", \"Quantitative contribution relative to other TFEB activation mechanisms unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Cryo-EM of the active FLCN complex revealed a ~90° reorientation of FLCN that breaks RagA contact and positions Arg164 for RagC catalysis; disruption of active-complex interfaces eliminated GAP activity and caused nuclear TFE3 retention without affecting S6K/4E-BP1, providing the structural basis for substrate-selective mTORC1 regulation.\",\n      \"evidence\": \"Cryo-EM of FLCN-FNIP2-SLC38A9-Rag-Ragulator active complex, interface mutagenesis, TFE3 localization and mTORC1 substrate phosphorylation assays\",\n      \"pmids\": [\"36103527\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How SLC38A9 triggers the conformational switch in FLCN mechanistically unclear\", \"Whether additional regulators facilitate the inactive-to-active transition in vivo unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"AKT1 was identified as the kinase phosphorylating FLCN at Ser62 downstream of insulin/mTORC2, and this phosphorylation inhibits RagC GAP activity, establishing FLCN as a convergence point for growth factor and amino acid signaling toward mTORC1.\",\n      \"evidence\": \"AKT1 kinase assay, Ser62 mutants, lysosomal fractionation with RagD mutants, mTORC1 activity and tumor growth assays\",\n      \"pmids\": [\"37083230\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Ser62 phosphorylation affects FLCN conformation or Rag binding directly not structurally resolved\", \"In vivo physiological significance beyond tumor xenografts not tested\", \"Single lab finding awaiting independent replication\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How FLCN's multiple regulatory inputs (ULK1 phosphorylation, AKT1 phosphorylation, GABARAP sequestration, FNIP2 degradation) are integrated in real time to calibrate RagC/D activity in different physiological contexts remains unresolved, as does the relative contribution of FLCN's Rab11A-dependent vesicular trafficking function versus its lysosomal GAP activity to tumor suppression.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified quantitative model integrating all FLCN regulatory inputs\", \"Structural basis of FLCN-Rab11A interaction and its relationship to GAP function unresolved\", \"Whether FLCN has additional enzymatic activities beyond RagC/D GAP unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 5, 6]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [4, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [6, 20, 21]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 18]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [21, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 4, 5, 6, 7, 32]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [10, 11]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [8, 9, 14]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13, 27]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [6, 7, 8]}\n    ],\n    \"complexes\": [\n      \"FLCN-FNIP1 complex\",\n      \"FLCN-FNIP2 complex\",\n      \"FLCN-FNIP2-Rag-Ragulator complex\"\n    ],\n    \"partners\": [\n      \"FNIP1\",\n      \"FNIP2\",\n      \"GABARAP\",\n      \"RRAGA\",\n      \"RRAGC\",\n      \"RAB11A\",\n      \"PRKAA1\",\n      \"TARDBP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}